Immunogenicity of HIV type 1 gp120 CD4 binding site phage mimotopes

AIDS Research and Human Retroviruses

Volumn 21, Issue 1, 2005, Pages 82-92

  Dorgham, Karim ^a   Dogan, Ismaïl ^a   Bitton, Natacha ^a   Parizot, Christophe ^a   Cardona, Valerie ^b   Debré, Patrice ^a   Hartley, Oliver ^b   Gorochov, Guy ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMINO ACID; CD4 ANTIGEN; COAT PROTEIN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G1; PEPTIDE LIBRARY;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ARTICLE; BACTERIOPHAGE; BINDING SITE; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; MOLECULAR EVOLUTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; VIRUS ENVELOPE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; BACTERIOPHAGES; BASE SEQUENCE; BINDING SITES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES;

EID: 13144250146     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.82     Document Type: Article

References (59)

1. Willey RL, Bonifacino JS, Potts BJ, Martin MA, and Klausner RD: Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci USA 1988;85:9580-9584.
2. Nara PL, Garrity RR, and Goudsmit J: Neutralization of HIV-1: A paradox of humoral proportions. FASEB J 1991;5:2437-2455.
3. Haynes BF, Pantaleo G, and Fauci AS: Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-328.
4. Moog C, Fleury HJ, Pellegrin I, Kim A, and Aubertin AM: Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997;71:3734-3741.
5. Letvin NL: Progress in the development of an HIV-1 vaccine. Science 1998;280:1875-1880.
6. Weiss RA, Clapham PR, Weber JN, Dalgleish AG, Lasky LA, and Berman PW: Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 1986;324:572-575.
7. Robert-Guroff M, Goedert JJ, Naugle CJ, Jennings AM, Blattner WA, and Gallo RC: Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: Results of a 6 year prospective study. AIDS Res Hum Retroviruses 1988;4:343-350.
8. Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, and Wolinsky SM: Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol 1998;72:1552-1576.
9. D'Souza MP, Geyer SJ, Hanson CV, Hendry RM, and Milman G: Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: An international collaboration. AIDS 1994;8:169-181.
10. D'Souza MP, Milman G, Bradac JA, McPhee D, Hanson CV, and Hendry RM: Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies. AIDS 1995;9:867-874.
11. Valenzuela A, Blanco J, Krust B, Franco R, and Hovanessian AG: Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells. J Virol 1997;71:8289-8298.
12. Schreiber M, Wachsmuth C, Muller H, Odemuyiwa S, Schmitz H, Meyer S, Meyer B, and Schneider-Mergener J: The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain. J Virol 1997;71:9198-9205.
13. Polzer S, Dittmar MT, Schmitz H, and Schreiber M: The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 2002;304:70-80.
14. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, and Arthos J: HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002;420:678-682.
15. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, and Sodroski JG: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393:705-711.
16. Poignard P, Klasse PJ, and Sattentau QJ: Antibody neutralization of HIV-1. Immunol Today 1996;17:239-246.
17. Parren PW, Burton DR, and Sattentau QJ: HIV-1 antibody - debris or virion? Nat Med 1997;3:366-367.
18. Burton DR: A vaccine for HIV type 1: The antibody perspective. Proc Natl Acad Sci USA 1997;94:10018-10023.
19. Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, and Burton DR: Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol 2003;77:642-658.
20. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, and Wilson IA: Crystal structure of a neutralizing human IGG against HIV-1: A template for vaccine design. Science 2001;293:1155-1159.
21. Zwick MB, Parren PW, Saphire EO, Church S, Wang M, Scott JK, Dawson PE, Wilson IA, and Burton DR: Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol 2003;77:5863-5876.
22. Boots LJ, McKenna PM, Arnold BA, Keller PM, Gorny MK, ZollaPazner S, Robinson JE, and Conley AJ: Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries. AIDS Res Hum Retroviruses 1997;13:1549-1559.
23. Zwick MB, Bonnycastle LL, Menendez A, Irving MB, Barbas CF, 3rd, Parren PW, Burton DR, and Scott JK: Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. J Virol 2001;75:6692-6699.
24. Burton DR, Barbas CF, 3rd, Persson MA, Koenig S, Chanock RM, and Lerner RA: A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 1991;88:10134-10137.
25. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al.: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-1027.
26. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, and Katinger H: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996;70:1100-1108.
27. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, and Moore JP: The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002;76:7293-7305.
28. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, and Burton DR: The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1 → 2 mannose residues on the outer face of gp120. J Virol 2002;76:7306-7321.
29. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, and Dimitrov DS: Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci USA 2002;99:6913-6918.
30. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, and Katinger H: A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001;17:1757-1765.
31. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, and Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-6647.
32. Conley AJ, Kessler JA 2nd, Boots LJ, Tung JS, Arnold BA, Keller PM, Shaw AR, and Emini EA: Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 1994;91:3348-3352.
33. Zwick MB, Wang M, Poignard P, Stiegler G, Katinger H, Burton DR, and Parren PW: Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol 2001;75:12198-12208.
34. Parren PW, Ditzel HJ, Gulizia RJ, Binley JM, Barbas CF 3rd, Burton DR, and Mosier DE: Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 1995;9:F1-6.
35. Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, and Koup RA: Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997;3:1389-1393.
36. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, and Burton DR: Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001;75:8340-8347.
37. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, and Birx DL: Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999;73:4009-4018.
38. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, and Lewis MG: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6:207-210.
39. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, Liska V, Ferrantelli F, Montefiori DC, McClure HM, Anderson DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Cavacini LA, Posner MR, Chou TC, Andersen J, and Ruprecht RM: Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001;75:7470-7480.
40. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, and Byrn RA: An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol 1991;146:4325-4332.
41. Fisch I, Kontermann RE, Finnern R, Hartley O, Soler-Gonzalez AS, Griffiths AD, and Winter G: A strategy of exon shuffling for making large peptide repertoires displayed on filamentous bacteriophage. Proc Natl Acad Sci USA 1996;93:7761-7766.
42. Houimel M, Mach JP, Corthesy-Theulaz I, Corthesy B, and Fisch I: New inhibitors of Helicobacter pylori urease holoenzyme selected from phage-displayed peptide libraries. Eur J Biochem 1999;262:774-780.
43. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, and Winter G: Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 1991;19:4133-4137.
44. McCafferty J, Griffiths AD, Winter G, and Chiswell DJ: Phage antibodies: Filamentous phage displaying antibody variable domains. Nature 1990;348:552-554.
45. Delmastro P, Meola A, Monaci P, Cortese R, and Galfre G: Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration. Vaccine 1997;15:1276-1285.
46. Smith GP and Scott JK: Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol 1993;217:228-257.
47. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
48. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, and Winter G: By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991;222:581-597.
49. Dattamajumdar AK, Jacobson DP, Hood LE, and Osman GE: Rapid cloning of any rearranged mouse immunoglobulin variable genes. Immunogenetics 1996;43:141-151.
50. Jones ST and Bendig MM: Rapid PCR-cloning of full-length mouse immunoglobulin variable regions. Biotechnology (NY) 1991;9:579.
51. Posner MR, Cavacini LA, Emes CL, Power J, and Byrn R: Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic Syndr 1993;6:7-14.
52. Dragic T, Hazan U, and Alizon M: In: Methods in Molecular Genetics. Academic Press, San Diego, CA, 1995, pp. 218-236.
53. Barbas CF 3rd, Collet TA, Amberg W, Roben P, Binley JM, Hoekstra D, Cababa D, Jones TM, Williamson RA, Pilkington GR, et al.: Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol 1993;230:812-823.
54. Bitton N, Verrier F, Debre P, and Gorochov G: Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120. Eur J Immunol 1998;28:4177-4187.
55. O'Neil KT, Hoess RH, Jackson SA, Ramachandran NS, Mousa SA, and DeGrado WF: Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library. Proteins 1992;14:509-515.
56. Jelinek R, Terry TD, Gesell JJ, Malik P, Perham RN, and Opella SJ: NMR structure of the principal neutralizing determinant of HIV-1 displayed in filamentous bacteriophage coat protein. J Mol Biol 1997;266:649-655.
57. Mian IS, Bradwell AR, and Olson AJ: Structure, function and properties of antibody binding sites. J Mol Biol 1991;217:133-151.
58. Mersmann M, Schmidt A, Tesar M, Schoneberg A, Welschof M, Kipriyanov S, Terness P, Little M, Pfizenmaier K, and Moosmayer D: Monitoring of scFv selected by phage display using detection of scFv-pIII fusion proteins in a microtiter scale assay. J Immunol Methods 1998;220:51-58.
59. Chen X, Scala G, Quinto I, Liu W, Chun TW, Justement JS, Cohen OJ, vanCott TC, Iwanicki M, Lewis MG, Greenhouse J, Barry T, Venzon D, and Fauci AS: Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat Med 2001;7:1225-1231.